MARKET

AIKI

AIKI

AIkido Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9123
+0.0305
+3.46%
After Hours: 0.8901 -0.0222 -2.43% 18:16 05/07 EDT
OPEN
0.8800
PREV CLOSE
0.8818
HIGH
0.9319
LOW
0.8703
VOLUME
917.70K
TURNOVER
--
52 WEEK HIGH
2.550
52 WEEK LOW
0.4656
MARKET CAP
81.11M
P/E (TTM)
-0.8903
1D
5D
1M
3M
1Y
5Y
AIkido Pharma Inc. Announces Participation in the Benzinga Global Small Cap Conference
Newsfile Corp · 3d ago
Accurate Diagnostic Solutions Remain Vital to Overcoming the Pandemic
, /PRNewswire/ -- While the U.S and the rest of the Western world is slowly recovering from the worst phases of the pandemic, is going through its worst wave yet. In 24 hours, the country reported more than 368,000 news cases, bringing the total number o...
PR Newswire - PRF · 5d ago
AIkido Pharma Announces Dr. Rachel Yehuda's Appearance at SXSW
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared at SXSW for a panel discussion entitled Psychedelics: Rewiring Mental Health Care. The Company is a proud supporter of Dr. Yehuda's research. The ...
PR Newswire · 04/27 14:12
BRIEF-Aikido Pharma Announces Withdrawal Of S-1 Registration Statement
reuters.com · 04/22 13:06
AIkido Pharma Expects Testing Data in 2Q >AIKI
AIkido Pharma Expects Testing Data in 2Q >AIKI
Dow Jones · 04/22 13:04
AIkido Pharma: Sufficiently Capitalized to Fund Research Activities, Pursue Emerging Opportunities >AIKI
AIkido Pharma: Sufficiently Capitalized to Fund Research Activities, Pursue Emerging Opportunities >AIKI
Dow Jones · 04/22 13:03
AIkido Pharma Announces Withdrawal of S-1 Registration Statement
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has withdrawn its S-1 Registration Statement that was previously filed with the U.S. Securities and Exchange Commission ("SEC"). The Registration Statement has n...
PR Newswire · 04/22 13:00
AIkido Pharma Notes Advancement In Radiopharmaceutical Research; Co Highlights Study Announcing Early Results From PSMA 617-Lu177 Study
AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical
Benzinga · 04/16 14:02
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIKI. Analyze the recent business situations of AIkido Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Robert Vander Zanden
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Anthony Hayes
Director
Robert Dudley
Director
Kyle Wool
Independent Director
Gregory Blattner
Independent Director
Tim Ledwick
Independent Director
Paul LeMire
No Data
  • All
  • Financials
  • Insiders
More
About AIKI
Aikido Pharma Inc., formerly Spherix Incorporated, is a biotechnology company. The Company is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, the Company is constantly seeking to grow its pipeline to treat its unmet medical needs in oncology.

Webull offers kinds of Aikido Pharma Inc stock information, including NASDAQ:AIKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIKI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIKI stock methods without spending real money on the virtual paper trading platform.